PETX Pemfailan SEC - Aratana Therapeutics, Inc.- Laporan Tahunan, Penyata Proksi, Prospektus

Statistik Asas

LEI	54930060AUDONOJ9U804
CIK	1509190

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Aratana Therapeutics, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.

July 29, 2019	15-12B	PETX / Aratana Therapeutics, Inc. 15-12B - - 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-35952 Aratana Therapeutics, Inc. (Exact name of registrant as specified
July 29, 2019	SC 13G	PETX / Aratana Therapeutics, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G 1 PETXSC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ARATANA THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 03874P101 (CUSIP Number) JULY 17, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate
July 22, 2019	SC 13G/A	PETX / Aratana Therapeutics, Inc. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
July 18, 2019	S-8 POS	PETX / Aratana Therapeutics, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on July 18, 2019 Registration No.
July 18, 2019	S-8 POS	PETX / Aratana Therapeutics, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on July 18, 2019 Registration No.
July 18, 2019	S-8 POS	PETX / Aratana Therapeutics, Inc. S-8 POS - - S-8 POS S-8 POS 1 a19-129385s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on July 18, 2019 Registration No. 333-189687 Registration No. 333-193472 Registration No. 333-203003 Registration No. 333-210232 Registration No. 333-216682 Registration No. 333-223653 Registration No. 333-230249 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment
July 18, 2019	S-8 POS	PETX / Aratana Therapeutics, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on July 18, 2019 Registration No.
July 18, 2019	S-8 POS	PETX / Aratana Therapeutics, Inc. S-8 POS - - S-8 POS S-8 POS 1 a19-129383s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on July 18, 2019 Registration No. 333-189687 Registration No. 333-193472 Registration No. 333-203003 Registration No. 333-210232 Registration No. 333-216682 Registration No. 333-223653 Registration No. 333-230249 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment
July 18, 2019	S-8 POS	PETX / Aratana Therapeutics, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on July 18, 2019 Registration No.
July 18, 2019	S-8 POS	PETX / Aratana Therapeutics, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on July 18, 2019 Registration No.
July 18, 2019	POS AM	PETX / Aratana Therapeutics, Inc. POS AM - - POS AM As filed with the Securities and Exchange Commission on July 18, 2019 Registration No.
July 18, 2019	POS AM	PETX / Aratana Therapeutics, Inc. POS AM - - POS AM As filed with the Securities and Exchange Commission on July 18, 2019 Registration No.
July 18, 2019	EX-3.2	Amended and Restated Bylaws of Aratana Therapeutics, Inc. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ARATANA THERAPEUTICS, INC. A DELAWARE CORPORATION ARTICLE I Offices Section 1. Registered Office. The registered office of Aratana Therapeutics, Inc. (the “corporation”) in the State of Delaware shall be in the City of Wilmington, County of New Castle or such other place as may be determined by the Board of Directors. Section 2. Other Offices. The corpora
July 18, 2019	EX-3.1	Amended and Restated Certificate of Incorporation of Aratana Therapeutics, Inc. Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF ARATANA THERAPEUTICS, INC. I. The name of this corporation is Aratana Therapeutics, Inc. (the “Corporation”). II. The address of the registered office of the Corporation in the State of Delaware is 251 Little Falls Drive, in the City of Wilmington, County of New Castle, Delaware 19808. The name of its registered agent at such address is Corporat
July 18, 2019	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 18, 2019 Aratana Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction (Commission (I.R.S. Employer
July 16, 2019	EX-99.1	Aratana Therapeutics’ Stockholders Adopt Merger Agreement with Elanco Animal Health Aratana Reports Voting Results from 2019 Special Meeting of Stockholders EX-99.1 Exhibit 99.1 Aratana Therapeutics Stockholders Adopt Merger Agreement with Elanco Animal Health Aratana Reports Voting Results from 2019 Special Meeting of Stockholders LEAWOOD, Kan., July 16, 2019 Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the voting
July 16, 2019	8-K	Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 16, 2019 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation) (Commi
July 2, 2019	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2019 Aratana Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation) (Commission
July 2, 2019	425	PETX / Aratana Therapeutics, Inc. 425 - Merger Prospectus - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2019 Aratana Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation) (Commission
June 17, 2019	DEFM14A	PETX / Aratana Therapeutics, Inc. DEFM14A - - DEFM14A Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS TABLE OF CONTENTS TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 7, 2019	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 6, 2019 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation)
May 29, 2019	425	PETX / Aratana Therapeutics, Inc. 425 - Merger Prospectus - 425 425 Filed by Aratana Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aratana Therapeutics, Inc. Commission File No: 001-35952 Stifel Dental & Veterinary Conference May 29, 2019 Safe Harbor Statement Special Note Regarding Forward-Looking Statements This presentation contains fo
May 9, 2019	425	ELAN / Elanco Animal Health Inc 425 Merger Prospectus 425 Filed by Elanco Animal Health Incorporated Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aratana Therapeutics, Inc.
May 9, 2019	10-Q	PETX / Aratana Therapeutics, Inc. 10-Q Quarterly Report 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35952
May 8, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2019 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation)
May 8, 2019	EX-99.1	Aratana Therapeutics Reports First Quarter 2019 Financial Results Continued revenue growth across portfolio of marketed pet therapeutics Exhibit 99.1 Aratana Therapeutics Reports First Quarter 2019 Financial Results Continued revenue growth across portfolio of marketed pet therapeutics LEAWOOD, Kan., May 8, 2019 — Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, announced its first quarter 2019 financial results
May 7, 2019	425	PETX / Aratana Therapeutics, Inc. 425 Merger Prospectus 425 425 Filed by Aratana Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aratana Therapeutics, Inc. Commission File No: 001-35952 The following social media communication was made available by Aratana Therapeutics, Inc. on May 7, 2019 on Craig Toomans LinkedIn account: The entire
April 30, 2019	425	PETX / Aratana Therapeutics, Inc. 425 (Merger Prospectus) 425 425 1 d709435d425.htm 425 Filed by Aratana Therapeutics, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 and Deemed Filed Pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Aratana Therapeutics, Inc. Commission File No.: 001-35952 The following is a form of email correspondence sent to certain consultants and advisors of Aratana Therapeutics, Inc. (“Arata
April 30, 2019	425	PETX / Aratana Therapeutics, Inc. 425 (Merger Prospectus) 425 425 1 d709441d425.htm 425 Filed by Aratana Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aratana Therapeutics, Inc. Commission File No: 001-35952 The following social media communications were made available by Aratana Therapeutics, Inc. on April 30, 2019 on the following soc
April 26, 2019	425	ELAN / Elanco Animal Health Inc 425 (Merger Prospectus) 425 Filed by Elanco Animal Health Incorporated Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aratana Therapeutics, Inc.
April 26, 2019	425	ELAN / Elanco Animal Health Inc 425 (Merger Prospectus) 425 Filed by Elanco Animal Health Incorporated Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Aratana Therapeutics, Inc.
April 26, 2019	EX-99.1	Aratana Therapeutics to be Acquired by Elanco Animal Health EX-99.1 Exhibit 99.1 Aratana Therapeutics to be Acquired by Elanco Animal Health Elanco announces formation of commercial team dedicated to veterinary specialty business Leawood, Kan. (April 26, 2019) – Aratana Therapeutics (NASDAQ: PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, announced it has signed an agreement to be acqui
April 26, 2019	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 d724775d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 26, 2019 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of
April 26, 2019	EX-2.1	Agreement and Plan of Merger, dated as of April 26, 2019, by and among Elanco Animal Health Incorporated, Elanco Athens Inc. and Aratana Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 to Elanco Animal Health Incorporated's Report on Form 8-K filed on April 26, 2019)** EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among ELANCO ANIMAL HEALTH INCORPORATED, ELANCO ATHENS INC. and ARATANA THERAPEUTICS, INC. Dated as of April 26, 2019 TABLE OF CONTENTS ARTICLE I. DEFINITIONS & INTERPRETATIONS 1 Section 1.1 Certain Definitions 1 Section 1.2 Additional Definitions 13 Section 1.3 Certain Interpretations 15 ARTICLE II. THE MERGER 16 Section 2.1 The Merger 16 Sec
April 26, 2019	EX-10.1	First Amendment, dated April 26, 2019, to the Amended and Restated Exclusive License, Development and Commercialization Agreement, dated July 5, 2018, by and between Aratana Therapeutics, Inc. and Pacira Pharmaceuticals, Inc. EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO AMENDED AND RESTATED EXCLUSIVE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This FIRST AMENDMENT TO THE AMENDED AND RESTATED EXCLUSIVE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Amendment”), is entered into and effective as of April 26, 2019 (the “Amendment Date”) by and between ARATANA THERAPEUTICS, INC., a Delaware corporation (“Ar
April 26, 2019	EX-2.1	Agreement and Plan of Merger, dated as of April 26, 2019, by and among Elanco Animal Health Incorporated, Elanco Athens Inc. and Aratana Therapeutics, Inc. (including the Form of Contingent Value Rights Agreement) EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among ELANCO ANIMAL HEALTH INCORPORATED, ELANCO ATHENS INC. and ARATANA THERAPEUTICS, INC. Dated as of April 26, 2019 TABLE OF CONTENTS ARTICLE I. DEFINITIONS & INTERPRETATIONS 1 Section 1.1 Certain Definitions 1 Section 1.2 Additional Definitions 13 Section 1.3 Certain Interpretations 15 ARTICLE II. THE MERGER 16 Section 2.1 The Merger 16 Sec
April 26, 2019	EX-99.1	Aratana Therapeutics to be Acquired by Elanco Animal Health EX-99.1 Exhibit 99.1 Aratana Therapeutics to be Acquired by Elanco Animal Health Elanco announces formation of commercial team dedicated to veterinary specialty business Leawood, Kan. (April 26, 2019) – Aratana Therapeutics (NASDAQ: PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, announced it has signed an agreement to be acqui
April 26, 2019	425	PETX / Aratana Therapeutics, Inc. 425 (Merger Prospectus) 8-K 425 1 d724775d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 26, 2019 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of
April 26, 2019	EX-10.1	First Amendment, dated April 26, 2019, to the Amended and Restated Exclusive License, Development and Commercialization Agreement, dated July 5, 2018, by and between Aratana Therapeutics, Inc. and Pacira Pharmaceuticals, Inc. EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO AMENDED AND RESTATED EXCLUSIVE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This FIRST AMENDMENT TO THE AMENDED AND RESTATED EXCLUSIVE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Amendment”), is entered into and effective as of April 26, 2019 (the “Amendment Date”) by and between ARATANA THERAPEUTICS, INC., a Delaware corporation (“Ar
April 26, 2019	EX-99.2	Elanco Strategic Investments Update April 26, 2019 Exhibit 99.2 Elanco Strategic Investments Update April 26, 2019 Important Information Important Information for Investors and Shareholders This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale woul
April 26, 2019	EX-99.1	Elanco Announces Agreement to Acquire Aratana Therapeutics; Completes Oncology Development Agreement with VetDC, Creates Specialty Veterinary Business Focus Elanco announces investor call for 9:00 am today Exhibit 99.1 Elanco Animal Health 2500 Innovation Way Greenfield, IN 46140 FOR IMMEDIATE RELEASE Investor Contact: Jim Greffet +1.317.383.9935 [email protected] Media Contact: Colleen Parr Dekker +1.317.989.7011 [email protected] Elanco Announces Agreement to Acquire Aratana Therapeutics; Completes Oncology Development Agreement with VetDC, Creates Specialty Veterinary Business F
April 26, 2019	EX-2.1	Agreement and Plan of Merger, dated as of April 26, 2019, by and among Elanco Animal Health Incorporated, Elanco Athens Inc. and Aratana Therapeutics, Inc. (including the Form of Contingent Value Rights Agreement) Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among ELANCO ANIMAL HEALTH INCORPORATED, ELANCO ATHENS INC. and ARATANA THERAPEUTICS, INC. Dated as of April 26, 2019 TABLE OF CONTENTS ARTICLE I. DEFINITIONS & INTERPRETATIONS 1 Section 1.1 Certain Definitions 1 Section 1.2 Additional Definitions 14 Section 1.3 Certain Interpretations 15 ARTICLE II. THE MERGER 16 Section 2.1 The Merger 16 Section 2.
April 26, 2019	425	ELAN / Elanco Animal Health Inc 425 (Merger Prospectus) 8-K 425 1 a19-894118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 26, 2019 Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter) Indiana 001-38661 82-5497352 (State or other jurisdic
April 19, 2019	DEFA14A	PETX / Aratana Therapeutics, Inc. DEFA14A DEFA14A 1 petx-20190419xdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriat
April 19, 2019	DEF 14A	PETX / Aratana Therapeutics, Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 15, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 petx-20190315x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 14, 2019 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or oth
March 13, 2019	S-8	PETX / Aratana Therapeutics, Inc. S-8 As filed with the Securities and Exchange Commission on March 13, 2019 Registration No.
March 13, 2019	10-K	PETX / Aratana Therapeutics, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 12 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35952 ARATANA THERAPEUTICS, INC. (Exact name of regi
March 13, 2019	EX-21.1	Subsidiaries of Aratana Therapeutics, Inc. Exhibit 21.1 Subsidiaries of Aratana Therapeutics, Inc.: NAME JURISDICTION OF ORGANIZATION Vet Therapeutics, Inc. Delaware Aratana Therapeutics NV (dissolved in December 2018) Belgium
March 12, 2019	EX-99.1	Aratana Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results Exhibit 99.1 Aratana Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results LEAWOOD, Kan., March 12, 2019 — Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, announced its fourth quarter and full year 2018 financial results and recent business highlights. “Our pr
March 12, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 petx-20190312x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 12, 2019 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or oth
February 8, 2019	SC 13G/A	PETX / Aratana Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment SC 13G/A 1 arat19a6.htm CUSIP NO. 03874P101 13G Page 1 of 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* ARATANA THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03874P101 (CUSIP Number) January 31, 2019 (Date of Event Which Requires Filin
February 5, 2019	EX-10.1	Employment Agreement, dated February 1, 2019, between Aratana Therapeutics, Inc. and Rhonda Hellums Exhibit 10.1 ARATANA THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of February 1, 2019 by and between ARATANA THERAPEUTICS, INC. (the “Company”) and Rhonda Hellums (the “Executive”). The Company and the Executive are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”. RECITALS A. As of
February 5, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 1, 2019 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporat
January 25, 2019	SC 13G/A	PETX / Aratana Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment arat18a5.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 03874P101 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* ARATANA THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03874P101 (CUSIP Number) December 31, 2018 (
January 22, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits 8-K 1 petx-20190122x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 17, 2019 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or o
January 22, 2019	EX-10.1	Letter Agreement, dated January 17, 2019, between Aratana Therapeutics, Inc. and Steven St. Peter, M.D. EX-10.1 2 petx-20190122xex101.htm EX-10.1 Exhibit 10.1 Aratana Therapeutics, Inc. 11400 Tomahawk Creek Parkway Suite 340 Leawood, KS 66211 January 17, 2019 By electronic delivery Steven St. Peter, M.D. Re: Resignation of Employment Dr. St. Peter: Aratana Therapeutics, Inc. (the “Company”) accepts your resignation from the office of President and Chief Executive Officer of the Com
January 22, 2019	EX-10.2	Amended and Restated Employment Agreement, dated January 18, 2019, between the Aratana Therapeutics, Inc. and Craig Tooman Exhibit 10.2 ARATANA THERAPEUTICS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of January 18, 2019 by and between ARATANA THERAPEUTICS, INC. (the “Company”) and Craig Tooman (the “Executive”). The Company and the Executive are hereinafter collectively referred to as the “Parties”, and individually re
January 22, 2019	SC 13G/A	PETX / Aratana Therapeutics, Inc. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
January 11, 2019	CORRESP	PETX / Aratana Therapeutics, Inc. 11400 Tomahawk Creek Pkwy, Suite 340, Leawood, KS 66211 Phone: 1-(844) 272-8262 Fax: (913) 904-9641 www.
January 10, 2019	SC 13D/A	PETX / Aratana Therapeutics, Inc. / Engaged Capital LLC - AMENDMENT NO. 4 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 Aratana Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03874P101 (CUSIP Number) glenn w. w
January 4, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 31, 2018 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorpora
December 28, 2018	8-K	Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 21, 2018 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorpora
November 2, 2018	10-Q	PETX / Aratana Therapeutics, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-3
November 1, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2018 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporat
November 1, 2018	EX-99.1	Aratana Therapeutics Reports Third Quarter 2018 Financial Results Exhibit 99.1 Aratana Therapeutics Reports Third Quarter 2018 Financial Results LEAWOOD, Kan., November 1, 2018 - Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, announced its third quarter 2018 financial results. For the third quarter ended September 30, 2018, Arata
August 20, 2018	SC 13D/A	PETX / Aratana Therapeutics, Inc. / Engaged Capital LLC - AMENDMENT NO. 3 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 Aratana Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03874P101 (CUSIP Number) glenn w. w
August 7, 2018	SC 13D/A	PETX / Aratana Therapeutics, Inc. / Engaged Capital LLC - AMENDMENT NO. 2 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Aratana Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03874P101 (CUSIP Number) glenn w. w
August 3, 2018	10-Q	PETX / Aratana Therapeutics, Inc. 10-Q (Quarterly Report) 10-Q 1 petx-20180630x10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to
August 3, 2018	EX-10.2	Amended and Restated Exclusive License, Development and Commercialization Agreement, dated July 5, 2018, between the Company and Pacira Pharmaceuticals, Inc. Exhibit 10.2 AMENDED AND RESTATED EXCLUSIVE LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This Amended and Restated Exclusive License, Development and Commercialization Agreement (this “Agreement”) is made effective as of July 5, 2018 (the “Effective Date”) by and between Pacira Pharmaceuticals, Inc., a California corporation with a principal place of business at 5 Sylvan Way, Parsippany,
August 3, 2018	EX-10.3	Amended and Restated Supply Agreement, dated July 5, 2018, between the Company and Pacira Pharmaceuticals, Inc. Exhibit 10.3 PACIRA PHARMACEUTICALS, INC. and ARATANA THERAPEUTICS, INC. AMENDED AND RESTATED SUPPLY AGREEMENT DATED AS OF JULY 5, 2018 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions
August 2, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 2, 2018 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporatio
August 2, 2018	EX-99.1	Aratana Therapeutics Reports Second Quarter 2018 Financial Results Exhibit 99.1 Aratana Therapeutics Reports Second Quarter 2018 Financial Results LEAWOOD, Kan., August 2, 2018 - Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, announced its second quarter 2018 financial results. For the second quarter ended June 30, 2018, Aratana r
August 1, 2018	8-K	Current Report 8-K 1 petx-20180801x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 27, 2018 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or othe
July 9, 2018	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 5, 2018 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation
June 8, 2018	DEFA14A	PETX / Aratana Therapeutics, Inc. DEFA14A DEFA14A 1 petx-20180608xdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriat
June 8, 2018	DEF 14A	PETX / Aratana Therapeutics, Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
June 1, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 1, 2018 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation or
May 21, 2018	8-K	PETX / Aratana Therapeutics, Inc. 8-K (Current Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 18, 2018 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation
May 21, 2018	EX-10.1	Cooperation Agreement, dated as of May 18, 2018, by and among Aratana Therapeutics, Inc., a Delaware corporation, Engaged Capital, LLC and the other parties listed on Annex A thereto Exhibit 10.1 COOPERATION AGREEMENT This Cooperation Agreement (this “Agreement”) is made and entered into as of May 18, 2018 (the “Agreement”) by and among Aratana Therapeutics, Inc., a Delaware corporation (the “Company”), and the persons and entities listed on Annex A hereto (collectively, the “Engaged Group” and, for clarity and as applicable, including each member thereof acting individually)
May 21, 2018	SC 13D/A	PETX / Aratana Therapeutics, Inc. / Engaged Capital LLC - EX. 99.1 - COOPERATION AGREEMENT Activist Investment begin 644 ex991to13da109455028052118.pdf M)5!$1BTQ+C4)>+CS],,R P(&]B:@H\/" (" @+U1Y<&4@+U!A9V4(" @ M+U!AM3QK2D$B5:2RL$(R8G^'H!]T8[I[%@N:&?I)0E8S';W]/2[>?'BQ\O/GM] M\:LOWNW%4KRN:[email protected];,=N]7K'R[^9U%M7'- M^K^KEC]]'C]U^OXL5ZJH;U-U^O\/-?@\KVO6?<=5WU:;EWZO7;W^P\47 MKR^E&CP^>V=1C'\X1XWVK2$@];KN!"/F\"NMOJDT7W'M^MMJX^N(T(6( M,:S,Z-1 T1IQMHV=?Q$M#F\,??P4VP\@M8A?=]A93BQZQ=DNHD.5]MQTB M(?
May 21, 2018	SC 13D/A	PETX / Aratana Therapeutics, Inc. / Engaged Capital LLC - AMENDMENT NO. 1 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Aratana Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03874P101 (CUSIP Number) glenn w. w
May 21, 2018	EX-99.2	JOINT FILING AGREEMENT Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the common stock, $0.001 par value per share, of Aratana Therapeutics, Inc., a Delaware corporation. Th
May 4, 2018	10-Q	PETX / Aratana Therapeutics, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35952
May 4, 2018	EX-10.1	Form of Confidentiality Agreement for Non-Employee Directors Exhibit 10.1 Form of Non-Employee Director Confidentiality Agreement , 201X In connection with my nomination and service as a member of the board of directors (a “Director”) of Aratana Therapeutics, Inc., a Delaware corporation (the “Company”), I hereby agree with the Company as follows: 1. In connection with my service as a Director, I may acquire certain confidential, proprietary or comp
May 3, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 petx-20180503x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 3, 2018 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other
May 3, 2018	EX-99.1	Aratana Therapeutics Reports First Quarter 2018 Financial Results EX-99.1 2 petx-20180503xex991.htm EX-99.1 Exhibit 99.1 Aratana Therapeutics Reports First Quarter 2018 Financial Results LEAWOOD, Kan., May 3, 2018 — Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, announced its first quarter 2018 financial results. In the first quart
April 27, 2018	10-K/A	PETX / Aratana Therapeutics, Inc. 10-K/A (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 12 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35952 ARATANA THERAPEUTICS, INC.
April 5, 2018	EX-99.1	Aratana Therapeutics Confirms Receipt of Board Nominations Exhibit 99.1 Aratana Therapeutics Confirms Receipt of Board Nominations LEAWOOD, Kan., April 5, 2018 – Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, confirmed that it has received a notice of nomination of three director candidates for election to the Company’s Board
April 5, 2018	8-K	Financial Statements and Exhibits, Other Events 8-K 1 petx-20180405x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 5, 2018 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or othe
April 5, 2018	EX-99.2	ENGAGED CAPITAL FLAGSHIP MASTER FUND, LP c/o ENGAGED CAPITAL, LLC 610 Newport Center Drive, Suite 250 Newport Beach, California 92660 Exhibit 99.2 ENGAGED CAPITAL FLAGSHIP MASTER FUND, LP c/o ENGAGED CAPITAL, LLC 610 Newport Center Drive, Suite 250 Newport Beach, California 92660 March , 2018 Re: Aratana Therapeutics, Inc. Dear : Thank you for agreeing to serve as a nominee for election to the Board of Directors of Aratana Therapeutics, Inc. (the “Company”) in connection with the proxy solicitation that Engaged Capital Flagship
April 5, 2018	EX-99.3	POWER OF ATTORNEY Exhibit 99.3 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Glenn W. Welling the undersigned’s true and lawful attorney-in-fact to take any and all action in connection with (i) the undersigned’s beneficial ownership of, or participation in a group with respect to, securities of Aratana Therapeutics, Inc., a Delaware corporation (the “Company”),
April 5, 2018	EX-99.1	JOINT FILING AND SOLICITATION AGREEMENT Exhibit 99.1 JOINT FILING AND SOLICITATION AGREEMENT WHEREAS, certain of the undersigned are stockholders, direct or beneficial, of Aratana Therapeutics, Inc., a Delaware corporation (the “Company”); WHEREAS, Engaged Capital Flagship Master Fund, LP, Engaged Capital Flagship Fund, LP, Engaged Capital Flagship Fund, Ltd., Engaged Capital, LLC, Engaged Capital Holdings, LLC and Glenn W. Welling (tog
April 5, 2018	SC 13D	PETX / Aratana Therapeutics, Inc. / Engaged Capital LLC - THE SCHEDULE 13D Activist Investment SC 13D 1 sc13d0945502804042018.htm THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Aratana Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class
March 14, 2018	S-8	PETX / Aratana Therapeutics, Inc. S-8 As filed with the Securities and Exchange Commission on March 14, 2018 Registration No.
March 14, 2018	EX-21.1	Subsidiaries of Aratana Therapeutics, Inc. Exhibit 21.1 Subsidiaries of Aratana Therapeutics, Inc.: NAME JURISDICTION OF ORGANIZATION Vet Therapeutics, Inc. Delaware Aratana Therapeutics NV Belgium
March 14, 2018	10-K	PETX / Aratana Therapeutics, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 12 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35952 ARATANA THERAPEUTICS, INC. (Exact name of regi
March 13, 2018	8-K	PETX / Aratana Therapeutics, Inc. 8-K (Current Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 13, 2018 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporatio
March 13, 2018	EX-99.1	Aratana Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results Exhibit 99.1 Aratana Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results LEAWOOD, Kan., March 13, 2018 — Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, announced its fourth quarter and full year 2017 financial results. For the quarter ended Decem
February 13, 2018	SC 13G/A	PETX / Aratana Therapeutics, Inc. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 5, 2018	SC 13G/A	PETX / Aratana Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment CUSIP NO. 03874P101 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* ARATANA THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03874P101 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Ch
January 11, 2018	8-K	Other Events 8-K GALLIPRANT EU MA update 01-11-2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
December 20, 2017	8-K	PETX / Aratana Therapeutics, Inc. 8-K (Current Report) 8K AT-014 Conditional Licensure Update December 20, 2017 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
December 18, 2017	424B5	$50,000,000 Common Stock Prospectus Supplement - 2017 ATM Filed Pursuant to Rule 424(b)(5) Registration No.
December 18, 2017	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K Sales and Business Updates ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
December 18, 2017	EX-10.1	Sales Agreement, dated as of December 18, 2017, by and between Aratana Therapeutics, Inc. and Cowen and Company LLC EX-10.1 2017 ATM Sales Agreement Exhibit 10.1 Aratana Therapeutics, Inc. ? $50,000,000 COmmon Stock ? SALES AGREEMENT ? December 18, 2017 ? Cowen and Company, LLC ?599 Lexington Avenue ?New York, NY 10022 ? Ladies and Gentlemen: ? Aratana Therapeutics, Inc. (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares.
November 27, 2017	424B5	$35,000,000 Common Stock Preliminary Pro Supp NOVEMBER 2017 The information in this preliminary prospectus supplement and the accompanying prospectus, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed.
November 27, 2017	8-K	Other Events 8-K Business Updates November 2017 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 13, 2017	8-K	Other Events 8K GALLIPRANT EU Press Release Status Update ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 3, 2017	10-Q	PETX / Aratana Therapeutics, Inc. 10-Q (Quarterly Report) 10-Q 1 petx-20170930x10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from
November 2, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 2, 2017 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporat
November 2, 2017	EX-99.1	Aratana Therapeutics Reports Third Quarter 2017 Financial Results Exhibit 991 Exhibit 99.1 ? ? ? Aratana Therapeutics Reports Third Quarter 2017 Financial Results ? LEAWOOD, Kan., November 2, 2017 ? Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, announced its third quarter 2017 financial results. For the quarter ended September 30, 201
August 14, 2017	CORRESP	Aratana Therapeutics ESP S-3 Acceleration Request Letter 11400 Tomahawk Creek Pkwy, Suite 340, Leawood, KS 66211 Phone: 1-(844) 272-8262 Fax: (913) 904-9641 www.
August 4, 2017	S-3	As filed with the Securities and Exchange Commission on August 4, 2017 S-3 1 petx-20170804xs3.htm S-3 As filed with the Securities and Exchange Commission on August 4, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Aratana Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 38-3826477 (State or other juris
August 4, 2017	EX-10.4	Second Amendment to Loan and Security Agreement, dated as of July 31, 2017, by and among Pacific Western Bank, in its capacity as collateral agent and the Lenders party thereto. Exhibit 10.4 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This Second Amendment to Loan and Security Agreement (the “Amendment”) is entered into as of July 31, 2017, by and among Pacific Western Bank, a California state chartered bank (“PWB”), in its capacity as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Agreement (as defined below) or oth
August 4, 2017	EX-10.3	Amendment, effective as of April 28, 2017, to the Collaboration, License, Development and Commercialization Agreement, dated April 22, 2016, by and between Aratana Therapeutics, Inc. and Eli Lilly and Company, acting on behalf of its Elanco Animal Health Division Exhibit 10.3 Confidential Treatment Requested by Aratana Therapeutics, Inc. AMENDMENT TO COLLABORATION, LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This Amendment to the Collaboration, License, Development and Commercialization Agreement (this “Amendment”), effective as of April 28, 2017, (the “Effective Date”) is entered into by and between Aratana Therapeutics, Inc., a Delaware corporat
August 4, 2017	EX-25.1	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T‑1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT EX-25.1 6 petx-20170804xex251.htm EX-25.1 Exhibit 25.1 File No. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T‑1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) WILMINGTON TRUST, NATIONAL ASSOCIATION (Exact name o
August 4, 2017	EX-12.1	Computation of Ratio of Earnings to Fixed Charges and Preferred Share Dividends (in thousands) Exhibit 12.1 Computation of Ratio of Earnings to Fixed Charges and Preferred Share Dividends (in thousands) Fiscal Year Ended December 31, 2012 Fiscal Year Ended December 31, 2013 Fiscal Year Ended December 31, 2014 Fiscal Year Ended December 31, 2015 Fiscal Year Ended December 31, 2016 Six Months Ended June 30, 2017 Fixed charges: Interest related to the Credit Facility* $ — $ 432 $ 1,060
August 4, 2017	EX-4.5	Aratana Therapeutics, Inc. Dated as of ___________, 20__ Wilmington Trust, National Association EX-4.5 2 petx-20170804xex45.htm EX-4.5 Exhibit 4.5 Aratana Therapeutics, Inc. INDENTURE Dated as of , 20 Wilmington Trust, National Association Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act.
August 4, 2017	10-Q	PETX / Aratana Therapeutics, Inc. 10-Q (Quarterly Report) 10-Q 1 petx-20170630x10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to
August 3, 2017	EX-99.1	Aratana Therapeutics Reports Second Quarter 2017 Financial Results Exhibit 991 Exhibit 99.1 ? ? ? Aratana Therapeutics Reports Second Quarter 2017 Financial Results ? LEAWOOD, Kan., August 3, 2017 ? Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, announced its second quarter 2017 financial results. For the quarter ended June 30, 2017, Ar
August 3, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 20170630 8K ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 3, 2017 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ? ? ? Delaware 001-35952 38-3826477 (State or other jurisdiction of
June 22, 2017	8-K	Current Report 20170621 8K ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2017 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ? ? ? Delaware 001-35952 38-3826477 (State or other jurisdiction of i
May 11, 2017	SC 13G/A	PETX / Aratana Therapeutics, Inc. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
May 9, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 10-Q 1 petx-20170331x10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to
May 8, 2017	8-K	Aratana Therapeutics 8-K (Current Report/Significant Event) 20170331 8K ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2017 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ? ? ? Delaware 001-35952 38-3826477 (State or other jurisdiction of inc
May 8, 2017	EX-99.1	Aratana Therapeutics Reports First Quarter 2017 Financial Results EX-99.1 2 petx-20170508xex991.htm EX-99.1 Exhibit 99.1 Aratana Therapeutics Reports First Quarter 2017 Financial Results LEAWOOD, Kan., May 8, 2017 — Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, announced its first quarter 2017 financial results. For the qu
May 4, 2017	424B5	5,000,000 Shares Common Stock FINAL Pro Supp Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.
May 4, 2017	EX-10.1	Securities Purchase Agreement, dated May 3, 2017, by and among Aratana Therapeutics, Inc. and the investors party thereto Exhibit 101 Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of May 3, 2017, by and among Aratana Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Schedule A attached hereto (each, a “Purchaser,” and collectively, the “Purchasers”). WHEREAS, the Company has prep
May 4, 2017	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K 1 petx-20170504x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 28, 2017 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or oth
May 4, 2017	EX-10.2	Placement Agency Agreement, dated May 3, 2017, by and between Aratana Therapeutics, Inc. and Barclays Capital, Inc. Exhibit 102 Exhibit 10.2 ? ? ? ARATANA THERAPEUTICS, INC. ? Common Stock ? PLACEMENT AGENCY AGREEMENT ? ? May 3, 2017 ? ? ? ? Barclays Capital Inc. 745 Seventh Avenue New York, NY 10019 ? ? Ladies and Gentlemen: ? Aratana Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes to issue and sell to certain investors (each, an ?Investor? and collectively, the ?Investors?) up to an aggre
May 4, 2017	424B5	Shares Common Stock Preliminary Pro Supp Table of Contents The information in this preliminary prospectus supplement and the accompanying prospectus, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed.
May 3, 2017	FWP	SECURITIES PURCHASE AGREEMENT FWP Filed Pursuant to Rule 433 Issuer Free Writing Prospectus dated May 3, 2017 (To Prospectus dated July 30, 2014) Registration Statement No.
April 28, 2017	DEFA14A	Aratana Therapeutics DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 28, 2017	DEF 14A	Aratana Therapeutics DEF 14A DEF 14A 1 petx-20170428xdef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box
March 14, 2017	S-8	Aratana Therapeutics S-8 S-8 1 petx-20170314xs8.htm S-8 As filed with the Securities and Exchange Commission on March 14, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARATANA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 38-3826477 (State or Other Jurisdiction of
March 14, 2017	EX-10.14(C)	Second Amendment to the Exclusive IP License Agreement for RQ-00000007, dated January 2, 2017, by and between Aratana Therapeutics, Inc. and RaQualia Pharma Inc. Exhibit 10.14(c) ? ? ? Second Amendment to the Exclusive IP License Agreement for RQ-00000007 between Aratana Therapeutics Inc. and RaQualia Pharma Inc. ? This is the Second Amendment (?Second Amendment?) to the Exclusive IP License Agreement for RQ-00000007 dated December 27, 2010 (the ?Agreement?) between Aratana Therapeutics Inc., a Delaware corporation (?Licensee?) and RaQualia Pharma Inc., a
March 14, 2017	EX-10.11(B)	First Amendment to Loan and Security Agreement, dated as of February 24, 2017, among Pacific Western Bank, as collateral agent, the lenders listed on Schedule 1.1 of the Loan and Security Agreement, Oxford Finance LLC, and Aratana Therapeutics, Inc. and Vet Therapeutics, Inc. Exhibit 10.11(b) ? ? ? FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This First Amendment to Loan and Security Agreement (the ?Amendment?) is entered into as of February 24, 2017, by and among Pacific Western Bank, a California state chartered bank (?PWB?), in its capacity as collateral agent (in such capacity, ?Collateral Agent?), the Lenders listed on Schedule 1.1 of the Agreement (as defined b
March 14, 2017	EX-21.1	Subsidiaries of Aratana Therapeutics, Inc.: Exhibit 21.1 ? Subsidiaries of Aratana Therapeutics, Inc.: ? NAME JURISDICTION OF ORGANIZATION Vet Therapeutics, Inc. Delaware Aratana Therapeutics NV Belgium ?
March 14, 2017	EX-10.13(C)	Second Amendment to the Exclusive IP License Agreement for RQ-00000005, dated January 2, 2017, by and between Aratana Therapeutics, Inc. and RaQualia Pharma Inc. ? Exhibit 10.13(c) ? ? Second Amendment to the Exclusive IP License Agreement for RQ-00000005 between Aratana Therapeutics Inc. and RaQualia Pharma Inc. ? This is the Second Amendment (?Second Amendment?) to the Exclusive IP License Agreement for RQ-00000005 dated December 27, 2010 (the ?Agreement?) between Aratana Therapeutics Inc., a Delaware corporation (?Licensee?) and RaQualia Pharma Inc., a
March 14, 2017	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2016 ☐ TRANSITION REPORT PURSUANT TO SECTION 12 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35952 ARATANA THERAPEUTICS, INC.
March 13, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 13, 2017 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorpor
March 13, 2017	EX-99.1	Aratana Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results Exhibit 991 Exhibit 99.1 ? Aratana Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results ? LEAWOOD, Kan., March 13, 2017 ? Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, announced its fourth quarter and full year 2016 financial results. For the quarter
February 13, 2017	SC 13G/A	Aratana Therapeutics 3G/A (Passive Acquisition of More Than 5% of Shares) SC 13G/A 1 d739781213g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Aratana Therapeutics, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 03874P101 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the ap
February 9, 2017	SC 13G/A	PETX / Aratana Therapeutics, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Aratana Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03874P101 (CUSIP Number) December 30, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
February 9, 2017	SC 13G/A	PETX / Aratana Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment arat16a3.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 03874P101 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ARATANA THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03874P101 (CUSIP Number) December 31, 2016 (
February 6, 2017	SC 13G/A	PETX / Aratana Therapeutics, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment SC 13G/A 1 arat.htm DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment # 5 Name of Issuer: ARATANA THERAPEUTICS, INC. Title of Class of Securities: Common Stock CUSIP Number: 03874P101 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GRO
February 6, 2017	8-K	Aratana Therapeutics (Current Report/Significant Event) Aratana Form 8-K (ENTYCE FDA Update) February 2017 (FINAL revised) ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 4, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 3, 2016	EX-99.1	Aratana Therapeutics Reports Third Quarter 2016 Financial Results Exhibit 991 Exhibit 99.1 Aratana Therapeutics Reports Third Quarter 2016 Financial Results LEAWOOD, Kan., November 3, 2016 — Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced its third quarter 2016 financial and operational results. For
November 3, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 petx-20161103x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2016 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State
October 5, 2016	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 5, 2016 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorpo
September 21, 2016	8-K	Current Report 8-K Jefferies Conference Business Updates ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
September 1, 2016	EX-10.1	Consulting and Separation Agreement, dated as of August 30, 2016 between Aratana Therapeutics, Inc. and Julia Stephanus Exhibit 101 Exhibit 10.1 ? CONSULTING AND SEPARATION AGREEMENT ? THIS CONSULTING AND SEPARATION AGREEMENT (the ?Agreement?) is entered into by and between Aratana Therapeutics, Inc., a Delaware corporation (the "Company") and the "Consultant" indicated on the signature page below. The Agreement shall become effective as of the ?Effective Date? indicated on the signature page below. INTRODUCTION: W
September 1, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events 8-K CCO Update and NOCITA Approval ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 9, 2016	SC 13G/A	PETX / Aratana Therapeutics, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 5, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 5, 2016	EX-10.3	Collaboration, License, Development and Commercialization Agreement, dated April 22, 2016, by and between Aratana Therapeutics, Inc. and Eli Lilly and Company, acting on behalf of its Elanco Animal Health Division Confidential Treatment Requested by Aratana Therapeutics, Inc. EXHIBIT 10.3 ? ? ? ? ? Collaboration, License, Development and Commercialization Agreement By and Between Aratana Therapeutics, Inc. and Eli Lilly and Company acting on behalf of its Elanco Animal Health Division Effective as of 22 April 2016 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request
August 5, 2016	EX-10.4	Co-Promotion Agreement, dated April 22, 2016, by and between Aratana Therapeutics, Inc. and Eli Lilly and Company, acting on behalf of its Elanco Animal Health Division Confidential Treatment Requested by Aratana Therapeutics, Inc. EXHIBIT 10.4 CO-PROMOTION AGREEMENT This Co-Promotion Agreement (this ?Agreement?), effective as of April 22, 2016 (the ?Effective Date?), is entered into by and between Aratana Therapeutics, Inc., a Delaware corporation and having its office at 11400 Tomahawk Creek Parkway, Suite 340, Leawood, KS 66211 (?Aratana?) and Eli Lilly and Co
August 5, 2016	EX-10.2	Non-Employee Director Compensation Program, as amended EXHIBIT 10.2 ? ARATANA THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (As Amended) Non-employee members of the board of directors (the ?Board?) of Aratana Therapeutics, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). The cash and equity compensation described in this Prog
August 4, 2016	8-K	Aratana Therapeutics 8-K (Current Report/Significant Event) 20160804 8K ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2016 ? ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ? ? Delaware 001-35952 38-3826477 (State or other jurisdiction
August 4, 2016	EX-99.1	Aratana Therapeutics Reports Second Quarter 2016 Financial Results Exhibit 991 Exhibit 99.1 ? ? Aratana Therapeutics Reports Second Quarter 2016 Financial Results ? LEAWOOD, Kan., August 4, 2016 ? Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced its second quarter 2016 financial and operational results. For the
June 30, 2016	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders 8-K Annual Meeting Results ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 30, 2016	EX-10.1	Employment Agreement, dated as of June 24, 2016, between Aratana Therapeutics, Inc. and Brent Standridge Exhibit 10.1 Exhibit 10.1 ARATANA THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of June 24, 2016 by and between ARATANA THERAPEUTICS, INC. (the “Company”) and Brent Standridge (the “Executive”). The Company and the Executive are hereinafter collectively referred to as the “Parties”, and individually referred to as a “Party”. Recita
May 6, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 20160331 10Q Q1 Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 5, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 petx-20160505x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2016 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or ot
May 5, 2016	EX-99.1	Aratana Therapeutics Reports First Quarter 2016 Financial Results Exhibit 99.1 Exhibit 99.1 ? Aratana Therapeutics Reports First Quarter 2016 Financial Results ? LEAWOOD, Kan., May 5, 2016 ? Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative pharmaceutical products for companion animals, announced its first quarter 2016 financial and operational results. For the quarter
April 28, 2016	DEFA14A	Aratana Therapeutics DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 28, 2016	DEF 14A	Aratana Therapeutics DEF 14A DEFA14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 25, 2016	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2016 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction (Commission (I.R.S. Emplo
March 16, 2016	S-8	Aratana Therapeutics S-8 201603 S8 As filed with the Securities and Exchange Commission on March 15, 2016 Registration No.
March 15, 2016	EX-10.11	Subordination, Non-Disturbance and Attornment Agreement, dated as of January 29, 2016, by and between Aratana Therapeutics, Inc., Academy 1740, Inc., and Commerce Bank EX-10.11 2 petx-20151231ex10116a054.htm EX-10.11 EXHIBIT 10.11 (Space above reserved for recorder’s use.) SUBORDINATION, NON-DISTURBANCE AND ATTORNMENT AGREEMENT THIS SUBORDINATION, NON-DISTURBANCE AND ATTORNMENT AGREEMENT (this "Agreement"), dated as of January 29, 2016, is entered into by and among Aratana Therapeutics, Inc., a Delaware corporation ("Tenant") whose mailing address is 11400 N. To
March 15, 2016	EX-21.1	Subsidiaries of Aratana Therapeutics, Inc.: EX-21.1 3 petx-20151231xex211.htm EX-21.1 Exhibit 21.1 Subsidiaries of Aratana Therapeutics, Inc.: NAME JURISDICTION OF ORGANIZATION Vet Therapeutics, Inc. Delaware Aratana Therapeutics NV Belgium
March 15, 2016	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2015 ☐ TRANSITION REPORT PURSUANT TO SECTION 12 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35952 ARATANA THERAPEUTICS, INC. Delaware 38-3826477 (State or other
March 14, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 20160310 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 14, 2016 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporatio
March 14, 2016	EX-99.1	Aratana Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results Exhibit 99.1 Exhibit 99.1 Aratana Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results LEAWOOD, Kan., March 14, 2016 ? Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced its fourth quarter 2015 and full year 2015 financial resu
February 12, 2016	SC 13G/A	PETX / Aratana Therapeutics, Inc. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 11, 2016	SC 13G/A	PETX / Aratana Therapeutics, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Aratana Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03874P101 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
February 3, 2016	SC 13G/A	PETX / Aratana Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment arat15a2.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 03874P101 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ARATANA THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03874P101 (CUSIP Number) December 31, 2015 (
January 28, 2016	SC 13G/A	PETX / Aratana Therapeutics, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.
December 29, 2015	8-K	Aratana Therapeutics 8-K (Current Report/Significant Event) 8k LR Retirement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 29, 2015 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of inco
November 17, 2015	8-K	Aratana Therapeutics 8-K (Current Report/Significant Event) Investor Day 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 17, 2015 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incor
November 6, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 petx-20150930x10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from t
November 6, 2015	EX-10.5	ARATANA THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (As Amended) EX-10.5 2 petx-20150930ex105ec2217.htm EX-10.5 Exhibit 10.5 ARATANA THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (As Amended) Non-employee members of the board of directors (the “Board”) of Aratana Therapeutics, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash a
November 5, 2015	8-K	Current Report 8-K 1 petx-20151105x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 5, 2015 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdi
November 5, 2015	EX-99.1	Aratana Therapeutics Reports Third Quarter 2015 Results EX-99.1 2 petx-20151105ex991fff922.htm EX-99.1 Exhibit 99.1 Aratana Therapeutics Reports Third Quarter 2015 Results KANSAS CITY, Kan., November 5, 2015 — Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, announced its third quarter 2015 financial and opera
November 3, 2015	SC 13G	PETX / Aratana Therapeutics, Inc. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
October 16, 2015	EX-10.1	ARATANA THERAPEUTICS, INC. Common Stock SALES AGREEMENT EX-10.1 3 petx-20151016ex1019a6a74.htm EX-10.1 Exhibit 10.1 EXECUTION VERSION ARATANA THERAPEUTICS, INC. Common Stock SALES AGREEMENT October 16, 2015 Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 Ladies and Gentlemen: Aratana Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to sell from time to time throug
October 16, 2015	424B5	$52,000,000 Common Stock 424B5 1 petx-20151016x10k.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-197414 PROSPECTUS SUPPLEMENT (To Prospectus dated July 30, 2014) $52,000,000 Common Stock We have entered into a sales agreement with Barclays Capital Inc., or Barclays, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms o
October 16, 2015	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8-K 1 petx-20151016x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2015 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdi
October 16, 2015	EX-10.2	Loan and Security Agreement, dated as of October 16, 2015, among Pacific Western Bank, as collateral agent, the lenders listed on Schedule 1.1 thereto, Oxford Finance LLC, and Aratana Therapeutics, Inc. and Vet Therapeutics, Inc. EX-10.2 4 petx-20151016ex102a1aa49.htm EX-10.2 Exhibit 10.2 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of October 16, 2015 (the “Effective Date”) among PACIFIC WESTERN BANK, a California state chartered bank with an office located at 406 Blackwell Street, Durham, North Ca
October 13, 2015	8-K	Aratana Therapeutics 8-K (Current Report/Significant Event) 8K HQ Lease AAFP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 8, 2015 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorp
October 13, 2015	EX-10.1	Office Building Lease, dated as of October 8, 2015, by and between Academy 1740, Inc. and Aratana Therapeutics, Inc. Exhibit 10.1 Office Building Lease Exhibit 10.1 OFFICE BUILDING LEASE THIS LEASE, dated as of October 8, 2015 (the ?Effective Date?) is made by and between Academy 1740, Inc., a Missouri corporation ("Landlord"), and ARATANA THERAPEUTICS, INC., a Delaware corporation ("Tenant"). WITNESSETH: Landlord, in consideration of the rent to be paid and the covenants and agreements to be performed by Tenant
October 5, 2015	EX-10.2	AMENDMENT NO. 2 TO SERVICES AGREEMENT EX-10.2 3 petx-20151005ex1023bcbdd.htm EX-10.2 Exhibit 10.2 AMENDMENT NO. 2 TO SERVICES AGREEMENT THIS AMENDMENT NO. 2 TO SERVICES AGREEMENT (this “Amendment”) is made and entered into effective as of September 29, 2015, by and between MPM Heartland House, LLC, a limited liability company organized under the laws of the State of Delaware (“MPM-HH”), and Aratana Therapeutics, Inc., a corporation or
October 5, 2015	EX-10.1	AMENDMENT NO. 2 TO LEASE Exhibit 10.1 HH Lease Amendment Exhibit 10.1 AMENDMENT NO. 2 TO LEASE THIS AMENDMENT NO. 2 TO LEASE (this ?Amendment?) is made and entered into effective as of September 29, 2015, by and between MPM Heartland House, LLC, a limited liability company organized under the laws of the State of Delaware (?Landlord?), and Aratana Therapeutics, Inc., a corporation organized under the laws of the State of
October 5, 2015	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 29, 2015 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation or org
September 25, 2015	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 24, 2015 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation or org
August 21, 2015	SC 13D/A	PETX / Aratana Therapeutics, Inc. / Avalon Ventures IX GP, LLC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under Rule 13d-1 of the Securities Exchange Act of 1934 (Amendment No. 3) Aratana Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03874P101 (CUSIP Number) Scott E. Oross, Esq. Paul Hastings LLP 4747 Executive Drive, 12th Floor San Diego, California 92121 (Name, Address an
August 10, 2015	SC 13G/A	PETX / Aratana Therapeutics, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 10, 2015	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2015 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation or organiz
August 7, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35952 ARAT
August 6, 2015	EX-99.1	Aratana Therapeutics Reports Second Quarter 2015 Results Exhibit 991 Exhibit 99.1 Aratana Therapeutics Reports Second Quarter 2015 Results Pipeline continues to mature towards objective of six products being marketed in 2016 KANSAS CITY, Kan., Aug 6, 2015 /PRNewswire/ - Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, an
August 6, 2015	8-K	Aratana Therapeutics 8-K (Current Report/Significant Event) 8K Q2 2015 Earnings Release UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
July 22, 2015	SC 13D/A	PETX / Aratana Therapeutics, Inc. / MPM BIOVENTURES V, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d80965dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Aratana Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03874P 10 1 (CUSIP Number) Ansbert Gadicke MPM Asset Management The John Hancock Tower 200 Clarendon Street, 54th Floor Boston,
July 22, 2015	EX-99.A	Joint Filing Statement EX-99.A Exhibit A Joint Filing Statement I, the undersigned, hereby express my agreement that the attached Schedule 13D (and any amendments thereto) relating to the beneficial ownership by the undersigned of the equity securities of Aratana Therapeutics, Inc. is filed on behalf of each of the undersigned. Date: July 21, 2015 MPM BIOVENTURES V GP LLC By: MPM BioVentures V LLC, its Managing Member B
July 20, 2015	SC 13D/A	PETX / Aratana Therapeutics, Inc. / Avalon Ventures IX GP, LLC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under Rule 13d-1 of the Securities Exchange Act of 1934 (Amendment No. 2) Aratana Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03874P101 (CUSIP Number) Scott E. Oross, Esq. Paul Hastings LLP 4747 Executive Drive San Diego, California 92121 (Name, Address and Telephone
June 18, 2015	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 18, 2015 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation or organiza
May 11, 2015	SC 13G/A	PETX / Aratana Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment arat15a1.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 03874P101 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ARATANA THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03874P101 (CUSIP Number) April 30, 2015 (Dat
May 8, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 petx-20150331x10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Co
May 7, 2015	EX-99.1	Aratana Therapeutics Reports First Quarter 2015 Results -- Announces full-enrollment of two pivotal field effectiveness studies -- Exhibit 991 Exhibit 99.1 Aratana Therapeutics Reports First Quarter 2015 Results - Announces full-enrollment of two pivotal field effectiveness studies - KANSAS CITY, Kan., May 7, 2015 /PRNewswire/ - Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, announced today
May 7, 2015	8-K	Aratana Therapeutics 8-K (Current Report/Significant Event) 8K Q1 2015 Earnings Release UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 28, 2015	DEFA14A	Aratana Therapeutics DEFA14A DEFA14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 28, 2015	DEF 14A	Aratana Therapeutics DEF 14A Proxy 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
March 25, 2015	S-8	Aratana Therapeutics S-8 201503 S8 As filed with the Securities and Exchange Commission on March 25, 2015 Registration No.
March 16, 2015	EX-21.1	Subsidiaries of Aratana Therapeutics, Inc.: Exhibit 21.1 Subsidiaries of Aratana Therapeutics, Inc.: NAME JURISDICTION OF ORGANIZATION Vet Therapeutics, Inc. Delaware Aratana Therapeutics NV Belgium
March 16, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K 1 petx-20141231x10k.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2014 ◻ TRANSITION REPORT PURSUANT TO SECTION 12 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35952 ARATANA THERAPEUTICS, INC. D
March 13, 2015	EX-99	Aratana Therapeutics Reports Fourth Quarter and Full Year 2014 Results -- Provides additional product updates -- -- Conference Call Friday, March 13, 2015, 8:30 a.m. Eastern Time -- Exhibit 991 Exhibit 99.1 Aratana Therapeutics Reports Fourth Quarter and Full Year 2014 Results - Provides additional product updates - - Conference Call Friday, March 13, 2015, 8:30 a.m. Eastern Time - KANSAS CITY, Kan., March 12, 2015/ PRNewswire/ - Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceuti
March 13, 2015	8-K	Aratana Therapeutics 8-K (Current Report/Significant Event) 20150312 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 9, 2015 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation
February 17, 2015	SC 13G/A	PETX / Aratana Therapeutics, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 17, 2015	SC 13G/A	PETX / Aratana Therapeutics, Inc. / Adage Capital Partners GP LLC - ARATANA THERAPEUTICS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ARATANA THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03874P101 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pur
February 12, 2015	SC 13G/A	PETX / Aratana Therapeutics, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Aratana Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03874P101 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate
February 4, 2015	SC 13G	PETX / Aratana Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment arat14in.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 03874P101 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ARATANA THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03874P101 (CUSIP Number) December 31, 2014 (D
November 12, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 petx-20140930x10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from t
November 10, 2014	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2014 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation or orga
November 10, 2014	EX-99.1	Aratana Therapeutics Reports Third Quarter 2014 Results —Conference Call Tomorrow, November 11, 2014, 8:30 a.m. Eastern Time— Exhibit 99.1 Aratana Therapeutics Reports Third Quarter 2014 Results —Conference Call Tomorrow, November 11, 2014, 8:30 a.m. Eastern Time— KANSAS CITY, Kan., November 10, 2014 — Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, today announced its third quarter 2014
October 10, 2014	SC 13G	PETX / Aratana Therapeutics, Inc. / Wellington Management Group LLP - DISCLOSURE DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aratana Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03874P101 (CUSIP Number) September 30, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t
September 19, 2014	EX-1.1	4,500,000 Shares ARATANA THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENT September 17, 2014 EX-1.1 Exhibit 1.1 EXECUTION VERSION 4,500,000 Shares ARATANA THERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENT September 17, 2014 Jefferies LLC 520 Madison Avenue New York, New York 10022 and Barclays Capital Inc. 745 Seventh Avenue New York, NY 10019 Ladies and Gentlemen: Aratana Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to you (the “Underwriters
September 19, 2014	8-K	Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 17, 2014 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation or
September 18, 2014	424B5	4,500,000 Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-197414 PROSPECTUS SUPPLEMENT (To Prospectus dated July 30, 2014) 4,500,000 Shares Common Stock We are offering 4,500,000 shares of our common stock. Our common stock is listed on The NASDAQ Global Market under the symbol “PETX.” On September 16, 2014, the last reported sale price of our common stock was $10.14 per share.
September 16, 2014	8-K	Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 16, 2014 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation or
September 16, 2014	424B5	Shares Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-197414 The information in this preliminary prospectus supplement and the accompanying prospectus, relating to an effective registration statement under the Securities Act of 1933, as amended, is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sel
September 16, 2014	FWP	Aratana Therapeutics, Inc. Free Writing Prospectus Published or Distributed by Media FWP 1 d790327dfwp.htm FWP Filed Pursuant to Rule 433 Issuer Free Writing Prospectus Dated September 16, 2014 (To Prospectus dated July 30, 2014, as supplemented by the Preliminary Prospectus Supplement dated September 16, 2014) Registration Statement No. 333-197414 Aratana Therapeutics, Inc. Free Writing Prospectus Published or Distributed by Media On September 15, 2014, FierceAnimalHealth (the “P
August 13, 2014	EX-10.1	ARATANA THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (As Amended) EX-10.1 2 d751141dex101.htm EX-10.1 Exhibit 10.1 ARATANA THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (As Amended) Non-employee members of the board of directors (the “Board”) of Aratana Therapeutics, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity c
August 13, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 12, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2014 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation or or
August 12, 2014	EX-99.1	Aratana Therapeutics Reports Second Quarter 2014 Results —Conference Call Today, August 12, 2014, 8:30 a.m. Eastern Time— EX-99.1 Exhibit 99.1 Aratana Therapeutics Reports Second Quarter 2014 Results —Conference Call Today, August 12, 2014, 8:30 a.m. Eastern Time— KANSAS CITY, Kan., August 12, 2014 — Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, today announced its second quarter 2
August 8, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2014 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation o
July 15, 2014	S-3	As filed with the Securities and Exchange Commission on July 15, 2014 Form S-3 Table of Contents As filed with the Securities and Exchange Commission on July 15, 2014 Registration No.
July 15, 2014	8-K	Financial Statements and Exhibits 8-K 1 d755816d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 15, 2014 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdictio
July 15, 2014	EX-99.1	OKAPI SCIENCES NV TABLE OF CONTENTS INDEPENDENT AUDITORS’ REPORT 2 BALANCE SHEETS 4 STATEMENTS OF OPERATIONS 5 STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY 6 STATEMENTS OF CASH FLOWS 7 NOTES TO THE FINANCIAL STATEMENTS 8 EX-99.1 Exhibit 99.1 OKAPI SCIENCES NV TABLE OF CONTENTS INDEPENDENT AUDITORS’ REPORT 2 BALANCE SHEETS 4 STATEMENTS OF OPERATIONS 5 STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY 6 STATEMENTS OF CASH FLOWS 7 NOTES TO THE FINANCIAL STATEMENTS 8 1 INDEPENDENT AUDITORS’ REPORT To the board of directors and shareholders We have audited the accompanying financial statements of Okapi Sciences NV (a develo
July 15, 2014	EX-12.1	Computation of Ratio of Earnings to Fixed Charges and Preferred Share Dividends (in thousands) Fiscal Year Ended December 31, 2010 (X) Fiscal Year Ended December 31, 2011 Fiscal Year Ended December 31, 2012 Fiscal Year Ended December 31, 2013 Three M EX-12.1 Exhibit 12.1 Computation of Ratio of Earnings to Fixed Charges and Preferred Share Dividends (in thousands) Fiscal Year Ended December 31, 2010 (X) Fiscal Year Ended December 31, 2011 Fiscal Year Ended December 31, 2012 Fiscal Year Ended December 31, 2013 Three Months Ended March 31, 2014 Fixed charges: Interest related to the Credit Facility $ — $ — $ — $ 432 $ 328 Interest portion of ren
July 15, 2014	EX-99.2	UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION EX-99.2 Exhibit 99.2 UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION The following unaudited pro forma consolidated financial information was prepared to give effect to the completed Vet Merger and the completed Okapi Acquisition. The unaudited pro forma consolidated statement of operations for the year ended December 31, 2013 gives effect to the Vet Merger and the Okapi Acquisition as if e
June 23, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 23, 2014 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation or organiza
June 20, 2014	8-K	Submission of Matters to a Vote of Security Holders - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 19, 2014 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation or
June 13, 2014	EX-10.1	SECOND AMENDMENT LOAN AND SECURITY AGREEMENT EX-10.1 Exhibit 10.1 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This Second Amendment to Loan and Security Agreement (the “Amendment”), is made as of June 13, 2014, by and among SQUARE 1 BANK (“Bank”), ARATANA THERAPEUTICS, INC. (“Aratana”) and VET THERAPEUTICS, INC. (“VTI”, and collectively with Aratana, “Borrower”). RECITALS Borrower and Bank are parties to that certain Loan and Security Ag
June 13, 2014	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2014 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation or
May 15, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35952 Ara
May 15, 2014	EX-10.2	AMENDMENT NO. 1 TO LEASE Exhibit 10.2 AMENDMENT NO. 1 TO LEASE THIS AMENDMENT NO. 1 TO LEASE (this ?Amendment?) is made and entered into effective as of May 1, 2014, by and between MPM Heartland House, LLC, a limited liability company organized under the laws of the State of Delaware (?Landlord?), and Aratana Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (?Tenant?). Capitalized terms
May 14, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2014 ARATANA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35952 38-3826477 (State or other jurisdiction of incorporation or
May 14, 2014	EX-99.1	Aratana Therapeutics Reports First Quarter 2014 Results —Conference Call Today, May 13, 2014, 4:45 p.m. Eastern Time— EX-99.1 Exhibit 99.1 Aratana Therapeutics Reports First Quarter 2014 Results —Conference Call Today, May 13, 2014, 4:45 p.m. Eastern Time— KANSAS CITY, Kan., May 13, 2014 — Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced its fi

PETX / Aratana Therapeutics, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

Statistik Asas

SEC Filings

SEC Filings (Chronological Order)